LONDON (Reuters) - Low doses of an experimental Chinese vaccine against the H5N1 bird flu virus produce an immune response in healthy people, according to early trial results reported on Thursday.
The vaccine made by Beijing-based Sinovac Biotech Co. Ltd contains a modified version of the whole virus plus an adjuvant, or additive, to increase effectiveness.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!